Commentary

Page 5

Recently published articles about Commentary

JCP
The Epidemiology and Global Burden of Schizophrenia
Commentary

January 18, 2023

This article explores the costs and burden of schizophrenia and provides an overview of disease prevalence, incidence, and trends over time.
,
JCP
Optimizing Therapy Selection, Sequencing in Schizophrenia
Commentary

January 18, 2023

This article summarizes the current treatment landscape in schizophrenia, along with contexts in which agents should be prescribed.
,
JCP
Defining and Achieving Treatment Recovery in Schizophrenia
Commentary

January 18, 2023

This article defines treatment recovery in schizophrenia and summarizes strategies clinicians can pursue to improve patient outcomes.
,
JCP
Actualizing and Sustaining Recovery-Oriented Care
Commentary

January 16, 2023

Jack Tsai, PhD, comments on intensity of therapy and scalability issues in a recent study of the Opening Doors to Recovery program for SMI.
JCP
Recent Advances in Screening for Mild Cognitive Impairment and Alzheimer Disease
Commentary

December 26, 2022

Among the most transformative Alzheimer disease discoveries is the existence of biomarkers which can manifest decades before onset of disease-related dementia.
,
JCP
The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease
Commentary

December 26, 2022

Navigating the associated differential diagnosis in AD is essential as various causes of cognitive impairment require different treatment strategies.
,
JCP
Developing Mental Illness Stigma–Reducing Interventions
Commentary

December 19, 2022

Research on antistigma interventions needs to look at sustained changes in attitudes and knowledge over time.
PCC
An Update on the Future of Wilson Disease Management
Commentary

November 29, 2022

Due to Wilson disease myriad manifestations, its rarity, and its range of symptoms, differential diagnosis may be challenging, leading to delays in treatment. This Neuroscience Commentary reviews diagnostic acumen...
JCP
Bipolar Disorder and PMDD: Comorbidity Conundrum
Commentary

October 26, 2022

Teri Pearlstein, MD, discusses a recent review that highlights the difficulties of diagnosing PMDD in women with bipolar disorder.
JCP
Relationship Between MDD and Medical Conditions
Commentary

October 19, 2022

This commentary by Rachel A. Weir, MD, and Mark Hyman Rapaport, MD, discusses the article by Alix M. Arnaud, MSc, and colleagues on the overlap between major depressive disorder...
,
JCP
Lost in Translation: The Value of Psychiatric Clinical Trials
Commentary

October 17, 2022

John C. Markowitz, MD, and Barbara L. Milrod, MD, assert the value of clinical trials in psychiatry and outline reasons why NIMH should resume supporting them.
,
JCP
Ketamine in the Real World: Where Do We Go From Here?
Commentary

September 14, 2022

Dr Wilkinson comments on recent data and developments in the use of ketamine for mood disorders.

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe